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The Relative Efficacy of Antifibrinolytics in
Adolescent Idiopathic Scoliosis
A Prospective Randomized Trial
Kushagra Verma, MD, MS, Thomas Errico, MD, Chris Diefenbach, MD, MS, Christian Hoelscher, BS, Austin Peters, BS,
Joseph Dryer, MD, Tessa Huncke, MD, Kirstin Boenigk, MD, and Baron S. Lonner, MD
Investigation performed at the Spine Center, Department of Orthopaedics, Hospital for Joint Diseases, New York University, New York, NY
Background: Antifibrinolytics can reduce intraoperative blood loss. The primary aim of this study was to determine the
efficacy of intraoperative tranexamic acid, epsilon-aminocaproic acid, and placebo at reducing perioperative blood loss
and the transfusion rate in patients with adolescent idiopathic scoliosis undergoing posterior spinal arthrodesis.
Methods: This is a prospective, randomized, double-blind comparison of tranexamic acid, epsilon-aminocaproic acid,
and placebo used intraoperatively in patients with adolescent idiopathic scoliosis. One hundred and twenty-five patients
with adolescent idiopathic scoliosis were randomly assigned to the tranexamic acid, epsilon-aminocaproic acid, or control
groups. Parameters recorded included estimated blood loss, hematocrit, blood product usage, drain output, and total
blood losses. The primary outcomes were intraoperative blood loss and postoperative drainage. Secondary outcomes
were transfusion requirements and hematocrit changes both intraoperatively and postoperatively.
Results: One hundred and twenty-five patients (ninety-seven female and twenty-eight male, with a mean age of fifteen
years) were randomized to receive tranexamic acid (thirty-six patients), epsilon-aminocaproic acid (forty-two patients), or
saline solution (forty-seven patients). The groups were similar at baseline, with one exception: the saline solution group
had a higher estimated blood volume at baseline than the tranexamic acid group. Both tranexamic acid and epsilon-
aminocaproic acid reduced the estimated blood loss per degree and estimated blood loss per pedicle screw. Epsilon-
aminocaproic acid, but not tranexamic acid, reduced estimated blood loss and estimated blood loss per level. Tranexamic
acid also reduced total blood losses compared with epsilon-aminocaproic acid or saline solution. In an analysis controlling
for level, degree, and number of anchors, tranexamic acid reduced drain output and total blood losses. Tranexamic acid or
epsilon-aminocaproic acid had a smaller decrease in hematocrit postoperatively. In an analysis controlling for the mean
arterial pressure during surgical exposure, tranexamic acid reduced estimated blood loss and total blood losses. Overall,
antifibrinolytics (tranexamic acid or epsilon-aminocaproic acid) reduced estimated blood loss, total blood losses, and the
decline in hematocrit postoperatively compared with saline solution. There was no difference among the groups with
respect to the transfusion rate, duration of surgery, levels fused, or pedicle screws placed.
Conclusions: Tranexamic acid and epsilon-aminocaproic acid reduced operative blood loss but not transfusion rate.
Tranexamic acid is more effective at reducing postoperative drainage and total blood losses compared with epsilon-
aminocaproic acid. Maintenance of the mean arterial pressure at <75 mm Hg during surgical exposure appears to be
critical for maximizing antifibrinolytic benefit.
Level of Evidence: Therapeutic Level I. See Instructions for Authors for a complete description of levels of evidence.
Disclosure: None of the authors received payments or services, either directly or indirectly (i.e., via his or her institution), from a third party in support of any
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ultilevel spinal arthrodesis has typically been associated
with substantial blood loss and transfusion requirements.
Patient-related factors affecting operative blood loss
include the severity and type of spinal deformity and the height
of the patient1-3. Surgery-dependent factors include the dura-
tion of the operation, prone positioning with free positioning
of the abdomen, procedure performed, combined anterior and
posterior approaches, number of vertebrae fused, number of ped-
icle screws placed, average mean arterial pressure during sur-
gery, blood salvage techniques, and the use of antifibrinolytic
medication4.
Large quantities of intraoperative and postoperative blood
loss require blood transfusion to maintain tissue perfusion and
prevent end-organ damage. The use of allogeneic blood, however,
confers additional risks for blood-borne pathogens, transfusion
reactions, and surgical site infection5-7.While blood conservation
techniques have improved transfusion needs, patients under-
going spinal arthrodesis may lose up to their entire blood vol-
ume or more for highly complex reconstructive procedures8.
Antifibrinolytics, such as tranexamic acid, epsilon-
aminocaproic acid (Amicar), and aprotinin, have become fa-
vored for cardiac and orthopaedic surgery, for which blood loss
is of major concern. Tranexamic acid is reported to be ten times
more potent than epsilon-aminocaproic acid as it binds more
strongly to the plasminogen molecule7,9. Although aprotinin was
highly effective, it has been associated with renal failure and has
been banned from clinical use in the United States10.
There is a paucity of data evaluating the optimal guide-
lines or indications for the administration of tranexamic acid
and epsilon-aminocaproic acid for spinal surgery. No study, to
our knowledge, has described Level-I evidence directly comparing
the efficacy of both treatment options. The purpose of this study
was to compare the relative efficacy of tranexamic acid, epsilon-
aminocaproic acid, and placebo in patients with adolescent id-
iopathic scoliosis. We hypothesized that tranexamic acid would
be more effective than epsilon-aminocaproic acid and saline
solution at reducing operative blood loss and postoperative
drainage in patients with adolescent idiopathic scoliosis.
Materials and Methods
Study Design
This is a prospective, randomized, double-blinded placebo-controlledtrial conducted at a single institution. This clinical trial was registered at
ClinicalTrials.gov (‘‘Tranexamic Acid [TXA] Versus Epsilon Aminocaproic Acid
[EACA] Versus Placebo for Spine Surgery,’’ NCT00958581). The protocol was
also reported in a previous study
11
.
Patient Selection
Following institutional review board approval, 125 patients with adolescent
idiopathic scoliosis undergoing posterior spinal arthrodesis were recruited for
the study. Informed consent was obtained from adult patients. For minors, a
parent or guardian provided consent while assent was obtained from the
minor.
Patient Randomization and Blinding
Prior to the operative procedure, patient deidentified identification numbers
were randomly assigned to the tranexamic acid (TXA; thirty-six patients), epsilon-
aminocaproic acid (EACA; forty-two patients), or placebo (forty-seven patients)
groups using computer-generated random assignment (Fig. 1). The random-
ization was performed in 2009 after institutional review board approval. Al-
location assignments were blinded from all persons, except the pharmacist, and
remained unchanged for the duration of the study. So-called unblinding from
the study was allowed at any time for medical necessity. These patients continued
to be followed per the protocol. Prospective patients who were approached for
inclusion in the study but declined participation had their deidentified iden-
tification passed over and their randomization allotment was not reviewed or
reused so as to prevent potential bias. Allocation assignments favored the saline
solution group over the treatment groups when the allocation assignments were
revealed.
Medication Dosage
For tranexamic acid, the loading dose was 10mg/kg infused over fifteenminutes,
while the maintenance dose was 1 mg/kg/hr. For epsilon-aminocaproic acid, the
TABLE I Demographics and Baseline Characteristics of Enrolled Patients
Parameter* TXA† EACA† Saline Solution P Value Comparison
No. of patients 36 42 47
Sex (M:F) 4:32 8:34 16:31
Age‡ (yr) 15.30 (2.37) 14.61 (1.89) 15.01 (2.37) 0.390 Overall
BMI‡ 21.19 (5.62) 21.92 (4.50) 22.69 (5.22) 0.423 Overall
No. of levels
arthrodesed‡
8.8 (2.3) 9.5 (2.8) 9.0 (2.0) 0.369 Overall
Coronal Cobb
angle‡ (deg)
54.6 (10.1) 53.4 (10.8) 54.1 (9.2) 0.871 Overall
No. of anchors
placed‡
16.3 (3.7) 16.6 (3.6) 16.1 (3.2) 0.775 Overall
Estimated blood
volume‡ (mL)
3672.(949) 3996.(1129) 4273.(1131) 0.035§ TXA vs. saline solution
*BMI = body mass index. †TXA = tranexamic acid, and EACA = epsilon-aminocaproic acid. ‡Values are given as the mean, with the standard
deviation in parentheses. §Significance achieved at p < 0.05.
e80(2)
THE JOURNAL OF BONE & JOINT SURGERY d J B J S .ORG
VOLUME 96-A d NUMBER 10 d MAY 21, 2014
THE RELAT IVE EFF ICACY OF ANTIF IBR INOLYT ICS IN
ADOLESCENT ID IOPATHIC SCOL IOS I S
loading dose was 100 mg/kg infused over fifteen minutes, while the maintenance
dose was 10 mg/kg/hr. Since tranexamic acid is reported to be ten times more
potent than epsilon-aminocaproic acid, the dose is adjusted in accordance
with existing guidelines
12-15
. The net volume of medication administered
was identical for either treatment option. The literature has also noted the
safe use of tranexamic acid at a loading dose of 100 mg/kg followed by a
maintenance dose of 10 mg/kg/hr. However, improved efficacy at this higher
dose of tranexamic acid has not been proven. Additionally, as reported in a
2008 review by Eaton
16
, the acquisition cost of these drugs is comparably low: $1
to $2 for a 5-g vial of epsilon-aminocaproic acid, and $20 to $25 for a 1 g vial of
tranexamic acid.
Surgical Correction of the Spine
Intraoperative exposure of the posterior vertebral elements was achieved by
careful dissection of the paraspinal musculature from the spinous process, lamina,
and facet. Soft-tissue releases and osseous osteotomies were performed to in-
crease flexibility followed by pedicle screw fixation. Local autologous and al-
lograft bone graft was used to achieve osseous fusion. Subfascial drains (Hemovac;
Zimmer, Warsaw, Indiana) were routinely placed at the wound site during closure
and were uniformly removed postoperatively when wound drainage was <40 mL
per eight-hour shift.
Data Collection
The preoperative, operative, and postoperative data gathered are outlined in the
Appendix. Estimated blood volume, or the preoperative total volume of blood,
was calculated as the weight of the patient (in kilograms) · 70mL/kg. Estimated
blood loss was estimated to be three times the volume in theCell Saver (Haemonetics,
Braintree, Massachusetts) for almost all patients. For patients in whom estimated
blood loss was £300 mL, intraoperative approximations were used. A transfu-
sion threshold was utilized. During surgery, the team was advised to transfuse
only for a hematocrit of £25 in patients with ongoing bleeding. Postoperatively,
a symptomatic patient with a hematocrit of £22 received a transfusion. Blood urea
nitrogen and creatinine levels were followed daily to monitor renal function.
Anesthesiologists were asked to maintain a mean arterial pressure of 60
to 80 mm Hg during the surgical exposure and anchor placement and a mean
arterial pressure of 70 to 90 during the surgical correction
17,18
. The so-called
average mean arterial pressure was estimated by measuring systolic and diastolic
blood pressure at fifteen-minute intervals during the procedure as described
Fig. 1
CONSORT26 (Consolidated Standards of Reporting Trials) flowchart.
e80(3)
THE JOURNAL OF BONE & JOINT SURGERY d J B J S .ORG
VOLUME 96-A d NUMBER 10 d MAY 21, 2014
THE RELAT IVE EFF ICACY OF ANTIF IBR INOLYT ICS IN
ADOLESCENT ID IOPATHIC SCOL IOS I S
previously
19
. All information was recorded onto a deidentified data col-
lection sheet by the researchers and then entered onto a protected electronic
database.
Outcomes
The primary study end points were intraoperative blood loss and postoperative
drainage. Secondary end points were transfusion requirements and hematocrit
changes both intraoperatively and postoperatively. The outcomes remained
unchanged during the study.
Statistical Methods
Descriptive analysis (mean, range, and standard deviation) was performed for
each parameter. Comparisons within, and between, groups were assessed
using analysis of variance with least significant difference post hoc tests and
the t test; the level of significance was set at p < 0.05. The initial power analysis
required pooling of data from several studies as no study directly compared
tranexamic acid and epsilon-aminocaproic acid. The estimated sample size
was between thirty-four and eighty patients per group, which was dependent
on the variable of interest (estimated blood loss, drain output, or transfusion
rate)
11
.
Source of Funding
Funding for this study was provided exclusively by departmental funds.
Results
Preliminary Data and Power Analysis
After sixty patients were enrolled (thirteen in the TXA group,seventeen in the EACA group, and thirty in the saline so-
lution group), a power analysis was repeated. Estimated blood
loss for each treatment arm was a mean (and standard devia-
tion) of 783 ± 514 mL for the TXA group, 493 ± 120 mL for the
EACA group, and 960 ± 175 mL for the saline solution group.
Drain output was a mean of 391 ± 113 mL for the TXA group,
538 ± 131 mL for the EACA group, and 568 ± 514 for the saline
solution group. The transfusion rate was more variable, with a
TABLE II Postoperative and Overall Blood Loss for Individual Groups
Individual Groups*
TXA EACA Saline Solution P Value Comparison
Drain total (mL)
Overall 789.(449) 1016.(422) 1034.(559) 0.027† TXA vs. saline solution
0.867 EACA vs. saline solution
0.043† TXA vs. EACA
Per level 90.5 (42.9) 111.0 (43.5) 117.9 (61.0) 0.038† TXA vs. saline solution
0.691 EACA vs. saline solution
0.097 TXA vs. EACA
Per degree 14.9 (7.6) 18.7 (7.3) 19.9 (11.1) 0.031† TXA vs. saline solution
0.688 EACA vs. saline solution
0.080 TXA vs. EACA
Per anchor 48.6 (26.0) 62.9 (26.5) 67.2 (37.9) 0.020† TXA vs. saline solution
0.669 EACA vs. saline solution
0.059 TXA vs. EACA
Total losses‡ (mL)
Overall 1531.(911) 1775.(853) 2116.(1201) 0.015† TXA vs. saline solution
0.161 EACA vs. saline solution
0.282 TXA vs. EACA
Per level 177.0 (95.3) 189.7 (79.9) 234.6 (111.6) 0.014† TXA vs. saline solution
0.057 EACA vs. saline solution
0.525 TXA vs. saline solution
Per degree 29.0 (16.2) 32.7 (14.9) 40.3 (22.9) 0.013† TXA vs. saline solution
0.095 EACA vs. saline solution
0.368 TXA vs. EACA
Per anchor 94.9 (53.6) 107.6 (46.0) 136.3 (92.1) 0.011† TXA vs. saline solution
0.076 EACA vs. saline solution
0.399 TXA vs. EACA
*The values are given as the mean, with the standard deviation in parentheses. Tranexamic acid (TXA) significantly reduced overall drainage
versus epsilon-aminocaproic acid (EACA), as well as all drainage parameters versus saline solution. TXA also significantly reduced all total losses
parameters versus saline solution. For the combined treatment group, total losses were significantly reduced versus saline solution.†Significance
achieved at p < 0.05. ‡Total losses consist of the estimated blood loss and the drain total.
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mean of 38% ± 51% for the TXA group, 6%± 24% for the EACA
group, and 20% ± 41% for the saline solution group. To detect
a significant difference with 80% power between tranexamic acid
and saline solution would require thirty-one, fourteen, and 128
patients per treatment arm for estimated blood loss, drain out-
put, and transfusion rate, respectively.
Patient Demographics and Surgical Strategy (Table I)
One hundred and twenty-five patients with adolescent idiopathic
scoliosis (ninety-seven female and twenty-eight male patients)
were randomly assigned to receive tranexamic acid (thirty-six
patients), epsilon-aminocaproic acid (forty-two patients), or saline
solution (forty-seven patients). There was no significant differ-
ence between the three groups with respect to age (mean, 15 ±
2.2 years; range, ten to twenty-one years), bodymass index (mean,
22 ± 5 kg/m2), preoperative coronal Cobb angle (mean, 54 ±
10), number of vertebral levels arthrodesed (mean, 9.1 ± 2.4), or
number of pedicle screws placed (16.3 ± 3.5). Patients who re-
ceived saline solution had a larger estimated blood volume
compared with patients who had tranexamic acid (p = 0.035). No
patients were excluded after enrollment.
Intraoperative Blood Loss (See Appendix)
Individual Groups (Fig. 2)
Tranexamic acid reduced estimated blood loss per degree
of Cobb angle (p = 0.042) and estimated blood loss per
pedicle screw (p = 0.042) compared with saline solution.
There was a trend toward lower estimated blood loss (p =
0.058) and estimated blood loss per level (p = 0.066) as well.
Epsilon-aminocaproic acid decreased estimated blood loss (p =
0.037), estimated blood loss per level (p = 0.022), estimated
blood loss per degree (p = 0.036), and estimated blood loss per
TABLE III Postoperative and Overall Blood Loss for Combined Group
TXA or EACA* Saline Solution* P Value
Drain total (mL)
Overall 912.0 (446) 1034.0 (559) 0.187
Per level 101.6 (44.1) 117.9 (61.0) 0.092
Per degree 17.0 (7.6) 19.9 (11.1) 0.069
Per anchor 56.3 (27.1) 67.2 (37.9) 0.088
Total losses† (mL)
Overall 1663.0 (882) 2116.0 (1202) 0.019‡
Per level 183.9 (87.0) 234.3 (111.6) 0.007‡
Per degree 31.0 (15.5) 40.3 (22.9) 0.008‡
Per anchor 101.8 (49.7) 136.3 (92.1) 0.010‡
*The values are given as the mean, with the standard deviation in paren-
theses. For the combined treatment group, total losses were significantly
reduced versus saline solution. †Total losses consist of the estimated
blood loss and the drain total. ‡Significance was achieved at p < 0.05
Fig. 2
Comparison of the three test substances with regard to intraoperative estimated blood loss (EBL). Epsilon-aminocaproic acid (EACA) significantly reduced
estimated blood loss compared with saline solution. Tranexamic acid (TXA) approached, but did not reach, significance for reduced estimated blood loss
comparedwith saline solution. Estimated blood loss was not significantly different between tranexamic acid and epsilon-aminocaproic acid. The values are
given as the mean, with the standard deviation represented by the error bars.
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pedicle screw (p = 0.029) compared with the patients who
received saline solution.
Combined Groups (Fig. 3)
Both antifibrinolyticmedications together (tranexamic acid or epsilon-
aminocaproic acid; seventy-eight patients) reduced estimated blood
loss (p= 0.019), estimated blood loss per level (p= 0.015), estimated
blood loss per degree (p = 0.015), and estimated blood loss per
pedicle screw (p = 0.013) compared with saline solution.
Postoperative and Total Losses
(Tables II and III)
Individual Groups (Figs. 4 and 5)
Drain output was lower for tranexamic acid compared with
epsilon-aminocaproic acid (p = 0.043) or saline solution (p = 0.027).
Comparedwith saline solution, tranexamic acid also lowered drain
output per level arthrodesed (p = 0.038), per degree of curve (p =
0.031), and per pedicle screw placed (p = 0.020). Tranexamic acid
also reduced total blood losses (total blood loss = drain output1
estimated blood loss) (p= 0.015), total blood loss per level (0.014),
total blood loss per degree (0.013), and total blood loss per anchor
(p = 0.011) compared with saline solution.
Combined Groups
The combined antifibrinolytic group decreased total blood loss
(p = 0.019), total blood loss per level (p = 0.007), total blood
loss per degree (p= 0.008), and total blood loss per pedicle screw
(p = 0.010) compared with saline solution.
Changes in Hematocrit (See Appendix)
Intraoperative Findings
For individual groups, hematocrit was measured at the time of
incision, start of pedicle screw placement, correction, and clo-
sure. At incision, the hematocrit was lower for tranexamic
acid (p = 0.010) and epsilon-aminocaproic acid (p = 0.008)
compared with saline solution. Hematocrit at pedicle screw
placement was also lower for tranexamic acid than for sa-
line solution (p = 0.005). Epsilon-aminocaproic acid had a
smaller change in hematocrit from incision to closure than saline
solution (p = 0.031).
The combined antifibrinolytic group had a smaller he-
matocrit at incision (p = 0.002) and at pedicle screw placement
(p = 0.021) than saline solution.
Postoperative Findings
For individual groups, the change in hematocrit from the time
in the postanesthesia care unit to postoperative day 1 was similar
between groups. From postoperative day 1 to day 2 and from
the time in the postanesthesia care unit to postoperative day 2,
the change in hematocrit was significantly reduced with epsilon-
aminocaproic acid, but not tranexamic acid, compared with saline
solution (p < 0.001 and p = 0.011, respectively).
Fig. 3
Comparison of the combined antifibrinolytics group (tranexamic acid [TXA] or epsilon-aminocaproic acid [EACA]) and the saline solution groupwith regard to
intraoperative estimated blood loss (EBL). Estimated blood loss was significantly reduced for the antifibrinolytics group. The values are given as the mean,
with the standard deviation represented by the error bars.
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Fig. 4
Fig. 5
Fig. 4 Comparison of the three test substances with regard to postoperative drainage. Tranexamic acid (TXA) significantly reduced drainage compared with
epsilon-aminocaproic acid (EACA) and compared with saline solution. Epsilon-aminocaproic acid did not significantly reduce drainage versus saline
solution. The values are given as the mean, with the standard deviation represented by the error bars. Fig. 5 Comparison of the three test substances with
regard to total losses (estimated blood loss [EBL]1 postoperative drainage). Tranexamic acid (TXA) significantly reduced total blood losses comparedwith
saline solution. Total blood losses were not significantly reduced between epsilon-aminocaproic acid (EACA) and saline solution as well as between
tranexamic acid and epsilon-aminocaproic acid. The values are given as the mean, with the standard deviation represented by the error bars.
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The combined antifibrinolytic group had a smaller decrease
in hematocrit from postoperative day 1 to day 2 (p = 0.002) and
from the time in the postanesthesia care unit to postoperative
day 2 (p= 0.012) than did the saline solution group (see Appendix).
Variations with Average Exposure Mean Arterial Pressure
(See Appendix)
There was no difference in the average mean arterial pressure
between the three treatment groups. Within each group, patients
were stratified according to ‘‘highmean arterial pressure’’ (‡75mm
Hg) and ‘‘low mean arterial pressure’’ (<75 mm Hg).
Mean Arterial Pressure of <75 mm Hg
For individual groups, tranexamic acid reduced estimated
blood loss (p = 0.042) and estimated blood loss per degree (p =
0.025) compared with saline solution (Fig. 6). Both tranexamic
acid and epsilon-aminocaproic acid independently reduced
estimated blood loss per level (p = 0.008 and p = 0.010, re-
spectively), estimated blood loss per pedicle screw (p = 0.023
and p = 0.030), and the change in hematocrit from the time in
the postanesthesia care unit to postoperative day 2 (p = 0.005
for both) compared with saline solution. Tranexamic acid, but
not epsilon-aminocaproic acid, lowered total blood losses
compared with saline solution also (p = 0.013).
The combined antifibrinolytic group had a smaller estimated
blood loss (p= 0.019), estimated blood loss per level (p= 0.005),
estimated blood loss per degree (p = 0.017), estimated blood
loss per pedicle screw (p = 0.008), total blood losses (p =
0.023), and postoperative hematocrit drop from the time in the
postanesthesia care unit to postoperative day 2 (p = 0.001) than
saline solution.
Mean Arterial Pressure of ‡75 mm Hg
For individual and combined groups, when the mean ar-
terial pressure was ‡75 mm Hg, there was no difference be-
tween treatment and control groups for any of the blood loss
parameters.
Transfusion Rates (See Appendix)
Of the 125 patients, thirty-four (27%) required forty-four units
of packed red blood cells during surgery, while nine (7%) re-
quired eleven units postoperatively. There was no difference in
intraoperative or postoperative transfusion rate between treat-
ment groups. In eleven patients, a blood transfusion was given
for a hematocrit above the suggested threshold. Exclusion of these
patients did not alter the result. There was also no difference
in the hematocrit before the incision between the twenty-eight
patients who had predonated blood (mean, 32.8 ± 3.4) or the
sixty-two patients who had not predonated blood (mean, 33.8 ±
3.4) (p = 0.215). Lastly, the transfusion rate was similar between
patients receiving autologous or allogeneic blood. Predonation
history was not available for thirty-five patients (28%).
Fig. 6
Intraoperativeestimatedblood loss (EBL)when themeanarterial pressure (MAP)was<75mmHg.Comparisonof the three test substanceswhencontrolled
for patients inwhom the averagemeanarterial pressurewasmaintained at <75mmHg throughout the procedure. Estimated blood losswas significantly reduced
between tranexamic acid and saline solution. There was no significant reduction between epsilon-aminocaproic acid (EACA) and saline solution or between
tranexamic acid and epsilon-aminocaproic acid. The values are given as the mean, with the standard deviation represented by the error bars.
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Exposure Times and Lengths of Stay (See Appendix)
Individual and Combined Groups
Tranexamic acid was associated with a shorter surgical exposure
(incision to pedicle screw placement) than epsilon-aminocaproic
acid (p= 0.027). There were no other differences in operative time
or hospital length of stay between treatment and control groups.
Deviations from Protocol and Complications
For one patient, concerns regarding ongoing bleeding led to so-
called unblinding during rod placement (saline solution group).
Ultimately, antifibrinolytic medication was not administered as
the procedure was near completion. For four patients, a drain was
not placed during skin closure because of unfamiliarity with the
study protocol. These patients were excluded from the ‘‘drain
output’’ analysis. One patient was readmitted for persistent wound
drainage. This quickly resolved after empiric antibiotic treatment.
No renal, thromboembolic, or other major complications were
observed.
Discussion
The role of antifibrinolytics tomanage blood loss has remainedlargely surgeon-dependent and is not the standard of care
for many spinal deformity surgeons. The majority of orthopaedic
studies have demonstrated the efficacy of tranexamic acid and
epsilon-aminocaproic acid over placebo in relation to blood
loss8,10-18. However, a reduction in intraoperative blood loss has
been inconsistently reported. In two recent Cochrane reviews7,14,
tranexamic acid was noted to be more efficacious than epsilon-
aminocaproic acid at reducing total blood losses, but neither
drug significantly reduced intraoperative bleeding. The most
recent review demonstrated a reduction in transfusion volume
with antifibrinolytic medications in scoliosis surgery, but could
not comment on the benefit of one medication over the other7.
Of the scoliosis studies examined in the Cochrane review, only
two adequately randomized patients and blinded both the surgeon
and anesthesiologist to the patient’s treatment7. Of the three studies
limited to children, only one described blood loss and transfu-
sion rate in both the intraoperative and postoperative period20.
The cardiac surgery literature has five prospective studies
directly comparing tranexamic acid and epsilon-aminocaproic
acid, but none had proper patient randomization and physician
blinding9,10,12,14,16. Comparing trials in all surgical fields including
cardiac surgery, tranexamic acid, but not epsilon-aminocaproic
acid, reduced the transfusion rate over placebo7,14. To our knowl-
edge, no orthopaedic study has directly compared tranexamic
acid and epsilon-aminocaproic acid.
Another important variable to consider is the efficacy of
tranexamic acid (and possibly epsilon-aminocaproic acid) at dif-
ferent dosages. A recent study of pediatric patients undergoing
craniosynostosis repair demonstrated an ability to maintain
blood tranexamic acid concentrations above known in vitro
therapeutic levels by using loading and maintenance doses five
times greater than those used in the present study21. However,
the authors of that study admit their dosage scheme may have
been higher than necessary as peak plasma levels were several
times above therapeutic level21.
The change in hematocrit postoperatively was smaller for
epsilon-aminocaproic acid and combined treatment groups com-
paredwith saline solution. Of note, the estimated blood volume
and the hematocrit prior to incisionwere lower for the treatment
groups compared with the saline solution group. Although un-
expected, this bias favored the control group and perhaps explains
why a difference was not observed intraoperatively between treat-
ment and control groups. Lastly, we found that maintenance of
the mean arterial pressure at <75 was important in mitigating
blood losses, in accordance with previous literature7,13-15,20,22-25. A
reduced intraoperative mean arterial pressure demonstrated an
improved efficacy for tranexamic acid that was greater than the
improvement of epsilon-aminocaproic acid versus saline so-
lution: all blood loss parameters, as well as total losses, were
significantly reduced (Fig. 6). To our knowledge, this is the first
study to describe intraoperative blood loss, the change in he-
matocrit during and after surgery, drain output, and transfu-
sion rate in a direct comparison.
While transfusion rate is a sought-after outcome to assess
the benefit of these medications, the decision to transfuse de-
pends on numerous intraoperative factors—patient comorbidities,
patient preference, preoperative blood donation, and clinical
judgment—all of which vary substantially with institution and
surgeon. These are difficult to control evenwith a Level-I study in
a relatively healthy homogenous population of patients with adoles-
cent idiopathic scoliosis. Tzortzopoulou et al. similarly reported
being unable to find a reduction in transfusion rate when reviewing
the cases of 254 prospectively randomized childrenwith idiopathic
scoliosis because of the wide confidence intervals between treat-
ment and control groups7. Transfusion rate, therefore, is not the
ideal standard to evaluate antifibrinolytic efficacy. Rather, intra-
operative estimated blood loss, drain output, total blood losses, and
the change in hematocrit during and after surgery are more useful.
It may be argued that patients with adolescent idiopathic
scoliosis have relatively fewer transfusion needs than adults with
scoliosis or childrenwith scoliosis secondary to a neuromuscular
condition. While this is true, patients with adolescent idiopathic
scoliosis were well suited for investigation because they repre-
sented a healthy homogenous group of patients free from use of
anticoagulant medications. Since blood losses are generally mod-
erate in this population, randomization to treatment or control
groups was reasonable. The benefit of decreased postoperative
wound drainage should also not be overlooked. These treat-
ments may prove useful for preventing postoperative wound
dehiscence and infections.
In conclusion, this study provides evidence that antifibri-
nolytic treatments reduce intraoperative blood loss but not trans-
fusion rate in adolescents with idiopathic scoliosis. Tranexamic
acid was about equally effective to epsilon-aminocaproic acid
in reducing operative blood losses and was superior in reducing
drain output and total losses compared with saline solution. Both
treatment groups had a smaller decline in hematocrit postop-
eratively compared with placebo. Controlling the mean arterial
pressure during surgery also appears to have an important role
for mitigating blood losses. Physicians should consider both the
intraoperative and postoperative benefits when deciding to use
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either tranexamic acid or epsilon-aminocaproic acid during surgery
to manage blood losses associated with spinal deformity surgery.
Appendix
Tables showing the preoperative, intraoperative, and post-
operative data collected; intraoperative blood loss data; he-
matocrit data; variations with average exposure mean arterial
pressure; transfusion data; and exposure times and lengths of stay
are available with the online version of this article as a data sup-
plement at jbjs.org. n
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